BillionToOne (BLLN) vs GRAIL (GRAL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GRAIL is the larger company by market cap ($6.26 billion vs $4.65 billion), about 1.3 times the size, while BillionToOne is growing revenue faster (+100.0% vs +17.2%). BillionToOne converts more of its revenue into profit, with a net margin of 2.4% versus -277.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLLN | GRAL |
|---|---|---|
| Share price | $98.52 | $140.26 |
| Market cap | $4.65B | $6.26B |
| 1-day change | +3.25% | +5.77% |
| YTD return | +16.58% | +54.94% |
| 1-year return | — | +82.18% |
| P/E ratio (TTM) | 156.37 | — |
| Forward P/E | 66.34 | — |
| EPS (TTM) | $0.63 | $-9.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $305.11M | $147.17M |
| Revenue growth (YoY) | +99.97% | +17.18% |
| Net income (latest FY) | $7.45M | $-408.35M |
| Gross margin | 68.32% | — |
| Operating margin | 5.25% | -381.98% |
| Net margin | 2.44% | -277.47% |
| 52-week high | $150.44 | $166.48 |
| 52-week low | $61.96 | $41.50 |
| Distance from 52-week high | -34.52% | -15.75% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +30.94% | -19.86% |
| Average volume | 689.14K | 940.82K |
| Shares outstanding | 42.64M | 44.67M |
| Employees | 713 | 910 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BillionToOne is more profitable, keeping 2.4 cents of every revenue dollar as net income versus -277.5 cents for GRAIL.
- BillionToOne grew revenue faster in its latest fiscal year (+99.97% vs +17.18%).
About BillionToOne
BLLN stock →BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection.
Health Care · Medical Specialities · 713 employees
About GRAIL
GRAL stock →GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer.
Health Care · Medical Specialities · 910 employees
BLLN vs GRAL FAQ
Which is bigger, BillionToOne or GRAIL?
GRAIL (GRAL) is larger, with a market capitalization of $6.26B compared with $4.65B for BillionToOne (BLLN).
Are BillionToOne and GRAIL in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.